Gain Therapeutics (GANX) Total Liabilities (2020 - 2026)

Gain Therapeutics has reported Total Liabilities for 7 years, with the latest figure at $4.1 million in Q2 2026.

• On a quarterly basis, Total Liabilities fell 32.71% year-over-year to $4.1 million in Q2 2026; TTM through Jun 2026 was $4.1 million, a 32.71% decrease from a year earlier, with the FY2025 full-year figure at $4.3 million, down 11.08% from the prior year.
• Total Liabilities was $4.1 million for Q2 2026 at Gain Therapeutics, down from $4.7 million in the prior quarter.
• The five-year high for Total Liabilities was $7.4 million in Q2 2024, with the low at $4.1 million in Q2 2026.
• Average Total Liabilities over 5 years is $5.6 million, with a median of $5.7 million recorded in 2022.
• The sharpest annual moves came in 2022 and 2026: Total Liabilities jumped 61.33% in 2022, then slumped 32.71% in 2026.
• Over 5 years, Total Liabilities stood at $5.2 million in 2022, then climbed by 15.54% to $6.0 million in 2023, then slipped by 20.67% to $4.8 million in 2024, then slipped by 11.08% to $4.3 million in 2025, then dropped by 2.92% to $4.1 million in 2026.
• The last three Total Liabilities figures came in at $4.1 million (Q2 2026), $4.7 million (Q1 2026), and $4.3 million (Q4 2025), per Business Quant data.